Latest Therapeutic Novelties and Patents in Pulmonary Hypertension

Author(s): Georgia F. Hardavella, Georgios S. Dionellis, Christina G. Kantza, Nikolaos G. Koulouris, Manos Alchanatis

Journal Name: Recent Patents on Cardiovascular Drug Discovery (Discontinued)

Volume 6 , Issue 1 , 2011


Recent advances in technology and novel pharmaceutical research findings have added new grounds in the fields of medical treatment and quality of life of patients diagnosed with pulmonary arterial hypertension (PAH). Collective assessment of new data is mandatory and useful for specialist medical doctors. This review aims to present the latest therapeutic developments of the last two years (2009-2010) in PAH. Moreover, recent patents (of the year 2010) regarding therapeutic novelties in PAH that expand treatment modalities, are hereby presented.

Keywords: Developments, patents, pulmonary arterial hypertension, therapeutic advances, therapeutic novelties, right heart catheterisation, PAH, phosphodiesterase-type 5, cGMP, sildenafil, PHIRST, right ventricular hypertrophy, eNOS, bosentan, sitaxsentan, ambrisentan, ambrisentan therapy, treprostinil, Rho kinase inhibitor, monocrotaline, azaindole-1, PASMCs, iloprost, XNT, right ventricular systolic, pressure, RVSP, Riociguat, epidermal growth factor, gefitinib, erlotinib, lapatinib, ACT-293987, selexipag, topiramate, tissue factor pathway inhibitor, tissue factor-mediated, downstream signaling pathway, calcitonin gene related peptide, CGRP, AMPK, AICAR, traditional chinese medicine, TCM

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [55 - 60]
Pages: 6
DOI: 10.2174/157489011794578491

Article Metrics

PDF: 29